AETERNA ZENTARIS INC (AEZS.CA) Stock Price, Forecast & Analysis
Canada - TSX:AEZS - CA0079756007 - Common Stock
AEZS.CA Key Statistics, Chart & Performance
The current stock price of AEZS.CA is 4.12 CAD. In the past month the price decreased by -18.25%. In the past year, price decreased by -66.34%.
AEZS.CA Latest News, Press Relases and Analysis
AEZS.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 470.58M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 406.00M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 179.49M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 118.44M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.88 | 54.57M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 34.18M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.67M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 24.31M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.56M | ||
| MPH.CA | MEDICURE INC | N/A | 13.05M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 10.72M | ||
| TELO.CA | TELO GENOMICS CORP | N/A | 7.53M |
Related stock screener links
About AEZS.CA
Company Profile
COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
Company Info
AETERNA ZENTARIS INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO 29486 CA
CEO: Klaus Paulini
Employees: 12
Phone: 18439003201
AETERNA ZENTARIS INC / AEZS.CA FAQ
What does AEZS do?
COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
What is the current price of AEZS stock?
The current stock price of AEZS.CA is 4.12 CAD. The price increased by 1.48% in the last trading session.
What is the dividend status of AETERNA ZENTARIS INC?
AEZS.CA does not pay a dividend.
How is the ChartMill rating for AETERNA ZENTARIS INC?
AEZS.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is AETERNA ZENTARIS INC (AEZS.CA) stock traded?
AEZS.CA stock is listed on the Toronto Stock Exchange exchange.
AEZS.CA Technical Analysis
AEZS.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AEZS.CA. AEZS.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AEZS.CA Financial Highlights
Over the last trailing twelve months AEZS.CA reported a non-GAAP Earnings per Share(EPS) of -15.41. The EPS decreased by -274.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.8% | ||
| ROE | -139.22% | ||
| Debt/Equity | 0.01 |
AEZS.CA Forecast & Estimates
For the next year, analysts expect an EPS growth of 68.75% and a revenue growth -2.27% for AEZS.CA